Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$15.35M$15.35M−29.2% vs Q2 2020 Net Income-$12.37M-$12.37MN/M vs Q2 2020 EPS Diluted-$0.33-$0.33N/M vs Q2 2020 Operating Income-$6,517,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,950,000N/M Margins · derivedOperating margin-42.5%−44.3 pt vs Q2 2020
Net margin-80.6%−69.8 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 3, 2021 · 34 d after period end